文献速递炎症性肠病

乌帕替尼16周延长诱导及52周维持治疗中度至重度活动性溃疡性结肠炎的疗效与安全性

Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis.
PubMed 文献 · Aliment Pharmacol Ther · 2023-11-27

两项诱导试验中,663例接受乌帕替尼45 mg每日一次诱导8周未达临床应答的患者中127例(19.2%)接受额外8周治疗,75例(59.1%)在第16周达临床应答并进入维持治疗;维持治疗第52周,15 mg组26.5%、30 mg组43.6%达临床缓解;延长暴露于45 mg期间带状疱疹发生率升高,未见其他新安全信号。

要点

  • 8周乌帕替尼45 mg诱导未应答者中19.2%接受额外8周治疗,59.1%在16周达临床应答。
  • 维持治疗52周临床缓解率:15 mg组26.5% vs 30 mg组43.6%。
  • 延长45 mg暴露16周期间带状疱疹发生率较前8周升高,无其他新安全信号。

核心结论

  • 8周乌帕替尼45 mg诱导治疗未达临床应答的患者,额外8周治疗可能获益。

研究设计与样本

  • 两项诱导试验中,8周乌帕替尼45 mg每日一次诱导未达临床应答的患者接受额外8周治疗;第16周达临床应答者按1:1重新随机分配至乌帕替尼15 mg或30 mg每日一次维持治疗52周。
  • 诱导疗效在第16周(整合)评估,维持疗效在第52周评估,安全性全程评估。

主要发现

  • 663例中127例(19.2%)在8周未达临床应答并接受额外8周治疗;127例中75例(59.1%)在第16周达临床应答并进入维持试验。
  • 维持治疗第52周,乌帕替尼15 mg组26.5%、30 mg组43.6%达临床缓解,两种剂量在其他所有终点均观察到疗效。
  • 延长45 mg暴露至16周期间带状疱疹发生率较同一人群前8周升高,未见其他新安全信号,其余结果与乌帕替尼已知安全性特征一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Upadacitinib is an oral, selective Janus kinase inhibitor. AIM: To assess the efficacy and safety of upadacitinib in patients with moderate-to-severe ulcerative colitis following 16-week extended induction therapy, and 52-week maintenance therapy in patients achieving clinical response after 16-week extended induction therapy METHODS: Patients without clinical response to 8 weeks' upadacitinib 45 mg once daily induction therapy in two induction trials were eligible for an additional 8 weeks of therapy. Patients achieving clinical response at Week 16 were subsequently re-randomised (1:1) to upadacitinib 15 or 30 mg once daily for 52-week maintenance therapy. Efficacy was assessed at induction Week 16 (integrated) and maintenance Week 52; safety was assessed throughout. RESULTS: Overall, 127/663 (19.2%) patients did not achieve clinical response to upadacitinib 45 mg at Week 8 and received an additional 8 weeks of therapy; 75/127 (59.1%) subsequently achieved clinical response at Week 16 and entered the maintenance trial. At Week 52, 26.5% of patients receiving upadacitinib 15 mg, and 43.6% receiving 30 mg, achieved clinical remission; efficacy was observed across all other endpoints with both doses. Herpes zoster rates increased with longer duration (16 weeks) of exposure to upadacitinib 45 mg during induction compared with the same population during the first 8 weeks. No other new safety signals were observed, and results are otherwise consistent with the known safety profile of upadacitinib. CONCLUSIONS: Patients without clinical response after 8 weeks' upadacitinib 45 mg induction therapy, may benefit from an additional 8 weeks of therapy. CLINICAL TRIAL REGISTRATION: NCT02819635; NCT03653026.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Panaccione R, Danese S, Zhou W, et al. Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther. 2023. PMID: 38010661. doi:10.1111/apt.17816

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。